Clinical Trials
48 trialsNCT03816163 2026-06-04
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT07628062 2026-06-04
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT07492680 2026-05-29
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT07221474 2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06731907 2026-05-26
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06119217 2026-05-13
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
Phase 2 Completed
NCT07578337 2026-05-13
NUMANTIA-2
Nelum Corp
Phase 2 Not yet recruiting
NCT04999969 2026-04-30
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
NCT06390059 2026-04-30
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
Phase 2 Completed
NCT07255404 2026-04-29
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
BioNTech SE
Phase 2 Recruiting
NCT07259317 2026-04-23
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT06906341 2026-04-14
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
Phase 2 Recruiting
NCT05852691 2026-03-16
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07376629 2026-01-29
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Huabo Biopharm Co., Ltd.
Phase 2 Enrolling by invitation
NCT04390399 2025-12-15
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05630183 2025-11-13
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Agenus Inc.
Phase 2 Active not recruiting
NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
NCT04623775 2025-10-20
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT03776812 2025-10-07
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Corcept Therapeutics
Phase 2 Completed
NCT02340117 2025-05-30
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
SynerGene Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT02322814 2023-04-13
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Hoffmann-La Roche
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT05068141 2021-10-15
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT00394082 2019-11-25
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Celgene
Phase 2 Completed
NCT00456846 2019-11-22
First Line Therapy for Patients With Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT02570711 2019-08-28
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Acerta Pharma BV
Phase 2 Terminated
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT02289456 2018-12-07
AboundPS2
Celgene
Phase 2 Completed
NCT02399137 2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2 Completed
NCT02017015 2017-09-26
PANC-001
Celgene
Phase 2 Completed
NCT01933061 2014-02-04
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Celgene
Phase 2 Withdrawn
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated